Getting Ahead of irAEs: Fostering Change in Structural Systems for Disadvantaged PopulationsPremiere Date: Monday, August 8, 2022
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Tuesday, August 8, 2023
|Ticiana Leal, MD (Moderator)
Associate Professor of Medicine
Department of Hematology and Oncology
Director, Thoracic Medical Oncology
Winship Cancer Institute
|Aung Naing, MD, FACP
Professor, Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
Editor-in-Chief, Journal of Immunotherapy and Precision Oncology
|Kristen Whitaker, MD, MS
Assistant Professor, Department of Medicine (Medical Oncology)
Georgetown Lombardi Comprehensive Cancer Center
Washington Hospital Center
When health care professionals (HCPs) use shared decision-making (SDM) with patients, patient satisfaction and trust improve; however, if SDM is not culturally aligned, health care inequities may be exacerbated. When using immune checkpoint inhibitors (ICIs) in cancer care, SDM is vital to help identify and address adverse events (AEs). Participation by patients from under-represented groups in clinical studies for ICIs has been low, primarily due to the social determinants of health (SDoH), HCP bias, and medical mistrust resulting from historic injustices. Because data on AEs and the efficacy of ICIs in ethnic and racial minority groups is insufficient, clinicians must use SDM and build trust to connect with patients from underserved communities and reduce inequities in cancer care. Additionally, by increasing diversity in health care systems and using patient navigation services, as well as best practices and protocols, health inequities in the use of ICIs in cancer care can be addressed. Building trust is essential to improving patient outcomes and reducing immune-related adverse events (irAEs).
In this OnDemand webcast, expert faculty will discuss how to use SDM to communicate treatment options, including ICIs, and build trust with patients to improve outcomes. They will present an overview of ICIs, the indications for use and common AEs, and then outline best practices and protocols for patients taking ICIs. Finally, faculty will address how to diagnosis and manage AEs to provide better adherence to ICI therapies for all patients with cancer.
At the end of this CE activity, participants should be able to:
- Recommend improvements to structural systems to better support irAE management in historically disadvantaged patient populations.
Supported by educational grants from Bristol Myers Squibb and Merck Sharpe & Dohme Corp.
Physicians, PAs, nurse practitioners, nurses, nurse navigators, and pharmacists, specializing in oncology, emergency medicine and/or primary care
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Dr. Leal reports the following financial relationships:
Advisory Board: AstraZeneca; Bayer; Boehringer-Ingelheim; Blueprint Medicines Corporation; Daiichi-Sankyo, Inc.; Eisai Inc.; EMD Serono; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Mirati Therapeutics, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Consultant: Amgen Inc.; AstraZeneca; Boehringer-Ingelheim; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Novocure; and Roche
Grants: Pfizer Inc.
Dr. Naing reports the following financial relationships:
Research Support: Amplimmune, Inc.; Arcus Biosciences, Inc.; ARMO BioSciences, Inc.; Atterocor, Inc.; Baxalta (I); Bristol Myers Squibb Company; Calithera Biosciences, Inc.; Chao Physician-Scientist Awards (I), Baylor College of Medicine; CytomX Therapeutics, Inc.; EMD Serono Inc.; Healios Oncology Nutrition, LLC; Immune Deficiency Foundation (I); ImmuneOncia Therapeutics, Inc.; Incyte; Jeffrey Modell Foundation (I); Karyopharm Therapeutics; Kymab; MedImmune; Lilly; Merck & Co., Inc.; Neon Therapeutics; NeoImmuneTech; National Cancer Institute (NCI); Novartis; Pfizer Inc.; PsiOxus Therapeutics; Regeneron Pharmaceuticals In; Surface Oncology; and TopAlliance BioSciences Inc.
Other Financial or Material Support: (Travel, accommodations, expenses) ARMO Biosciences, Inc.
Dr. Whitaker reports the following financial relationships:
Grants: The V Foundation for Cancer Research
Research Support: The V Foundation for Cancer Research and National Institutes of Health (NIH)
Other Financial or Material Support: Axis Medical Education and Total Health Conferencing
The following peer reviewer and CME Outfitters staff have no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).